Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
NCT03345784 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2024-02-20
Summary
This phase I trial studies the side effects and best dose of adavosertib when given together with external beam radiation therapy and cisplatin in treating patients with cervical, vaginal, or uterine cancer. Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. External beam radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving adavosertib, external beam radiation therapy, and cisplatin may work better in treating patients with cervical, vaginal, or uterine cancer.
Conditions
- Cervical Carcinoma
- Endometrioid Adenocarcinoma
- Malignant Female Reproductive System Neoplasm
- Recurrent Cervical Carcinoma
- Stage I Uterine Corpus Cancer AJCC v7
- Stage I Vaginal Cancer AJCC v6 and v7
- Stage IA Uterine Corpus Cancer AJCC v7
- Stage IB Cervical Cancer AJCC v6 and v7
- Stage IB Uterine Corpus Cancer AJCC v7
- Stage IB2 Cervical Cancer AJCC v6 and v7
- Stage II Cervical Cancer AJCC v7
- Stage II Uterine Corpus Cancer AJCC v7
- Stage II Vaginal Cancer AJCC v6 and v7
- Stage IIA Cervical Cancer AJCC v7
- Stage IIB Cervical Cancer AJCC v6 and v7
- Stage III Cervical Cancer AJCC v6 and v7
- Stage III Uterine Corpus Cancer AJCC v7
- Stage III Vaginal Cancer AJCC v6 and v7
- Stage IIIA Cervical Cancer AJCC v6 and v7
- Stage IIIA Uterine Corpus Cancer AJCC v7
- Stage IIIB Cervical Cancer AJCC v6 and v7
- Stage IIIB Uterine Corpus Cancer AJCC v7
- Stage IIIC Uterine Corpus Cancer AJCC v7
- Vaginal Carcinoma
Interventions
- DRUG
-
Adavosertib
Given PO
- DRUG
-
Given IV
- RADIATION
-
External Beam Radiation Therapy
Undergo external beam radiation therapy
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Stephanie Lheureux · University Health Network Princess Margaret Cancer Center LAO
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-05-29
- Primary Completion
- 2022-05-10
- Completion
- 2022-05-10
- FDA Drug
- Yes
Countries
- United States
- Canada
Study Locations
More Related Trials
-
Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02272790 ·Status: COMPLETED ·Phase: PHASE2
-
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
NCT00807768 ·Status: UNKNOWN ·Phase: PHASE3
-
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
NCT00005830 ·Status: COMPLETED ·Phase: PHASE1
-
Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02659241 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
NCT00006011 ·Status: COMPLETED ·Phase: PHASE3
-
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer
NCT01264432 ·Status: COMPLETED ·Phase: PHASE1
-
Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma
NCT00504257 ·Status: COMPLETED ·Phase: PHASE2
-
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
NCT03968406 ·Status: RECRUITING ·Phase: PHASE1
-
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
NCT00545792 ·Status: COMPLETED ·Phase: PHASE2
-
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck
NCT00063895 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT02101775 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
NCT01357161 ·Status: COMPLETED ·Phase: PHASE2
-
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT00989651 ·Status: COMPLETED ·Phase: PHASE1
-
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
NCT02208375 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer
NCT00002493 ·Status: COMPLETED ·Phase: PHASE3
-
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
NCT00492778 ·Status: UNKNOWN ·Phase: PHASE2
-
Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies
NCT04395079 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis
NCT00002949 ·Status: COMPLETED ·Phase: PHASE1
-
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02446600 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
NCT00575952 ·Status: COMPLETED ·Phase: PHASE1
-
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
NCT03924245 ·Status: TERMINATED ·Phase: PHASE1
-
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT03914612 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy
NCT03607955 ·Status: WITHDRAWN ·Phase: PHASE1
-
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
NCT04739800 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol
NCT02501954 ·Status: COMPLETED ·Phase: PHASE3